Open Access

Coenzyme Q10 defects may be associated with a deficiency of Q10-independent mitochondrial respiratory chain complexes

  • Konstantina Fragaki1, 2,
  • Annabelle Chaussenot1, 2,
  • Jean-François Benoist3,
  • Samira Ait-El-Mkadem1, 2,
  • Sylvie Bannwarth1, 2,
  • Cécile Rouzier1, 2,
  • Charlotte Cochaud1 and
  • Véronique Paquis-Flucklinger1, 2Email author
Biological Research201649:4

DOI: 10.1186/s40659-015-0065-0

Received: 24 September 2015

Accepted: 30 December 2015

Published: 8 January 2016

Abstract

Background

Coenzyme Q10 (CoQ10 or ubiquinone) deficiency can be due either to mutations in genes involved in CoQ10 biosynthesis pathway, or to mutations in genes unrelated to CoQ10 biosynthesis. CoQ10 defect is the only oxidative phosphorylation disorder that can be clinically improved after oral CoQ10 supplementation. Thus, early diagnosis, first evoked by mitochondrial respiratory chain (MRC) spectrophotometric analysis, then confirmed by direct measurement of CoQ10 levels, is of critical importance to prevent irreversible damage in organs such as the kidney and the central nervous system. It is widely reported that CoQ10 deficient patients present decreased quinone-dependent activities (segments I + III or G3P + III and II + III) while MRC activities of complexes I, II, III, IV and V are normal. We previously suggested that CoQ10 defect may be associated with a deficiency of CoQ10-independent MRC complexes. The aim of this study was to verify this hypothesis in order to improve the diagnosis of this disease.

Results

To determine whether CoQ10 defect could be associated with MRC deficiency, we quantified CoQ10 by LC-MSMS in a cohort of 18 patients presenting CoQ10-dependent deficiency associated with MRC defect. We found decreased levels of CoQ10 in eight patients out of 18 (45 %), thus confirming CoQ10 disease.

Conclusions

Our study shows that CoQ10 defect can be associated with MRC deficiency. This could be of major importance in clinical practice for the diagnosis of a disease that can be improved by CoQ10 supplementation.

Keywords

Mitochondrial disease CoQ10 deficiency Respiratory chain Spectrophotometry LC-MSMS

Background

Coenzyme Q10 (CoQ10 or ubiquinone) is a lipid-soluble component of the mitochondrial inner membrane that plays a central role in mitochondrial respiratory chain (MRC) function, as electrons carrier from complexes I and II to complex III, thus participating in ATP production [1].

CoQ10 deficiency encompasses several clinical phenotypes such as encephalomyopathy, severe infantile multisystemic disease, cerebellar ataxia, isolated myopathy or nephrotic syndrome [2]. CoQ10 deficiency can be primary, due to mutations in genes involved in CoQ10 biosynthesis or secondary, due to mutations in genes unrelated to CoQ10 biosynthesis [3]. Secondary CoQ10 deficiency has been described in patients with mitochondrial DNA (mtDNA) mutations or deletions, with mtDNA depletion syndrome (MDS) [46] and in patients with mutations in APTX [7], ETFDH [8, 9], BRAF [10], ACADVL or NPC genes [11]. CoQ10 defect is the only oxidative phosphorylation (OXPHOS) disorder that can be clinically improved after oral CoQ10 supplementation with limitation of neurological and renal manifestations, amelioration of muscular symptoms and attenuation of histological alterations. Early treatment is crucial to prevent irreversible damage in organs such as the kidney and the central nervous system [1214]. Reduced activities of CoQ10-dependent enzymes by spectrophotometric analysis (segments I + III or G3P + III and II + III) are evocative of CoQ10 deficiency but direct measurement of CoQ10 levels is the most reliable test for diagnosis [15]. It is widely reported in the literature that, in patients with CoQ10 deficiency, enzymatic activities of MRC complexes I, II, III, IV, V are normal [16]. In a previous report, we described an 11-year-old boy presenting with a propionic acidemia who succumbed to acute heart failure in the absence of decompensation of his metabolic condition. Spectrophotometric analysis in liver identified CoQ10-dependent activities deficiency that was associated with MRC enzymatic defect. Secondary CoQ10 deficiency was likely involved in the development of heart complications in this child and we hypothesized that a CoQ10-defect may be associated with MRC deficiency [17]. The aim of this study was to verify this hypothesis in order to improve the diagnosis of this disease.

Over a 6-year period, we analyzed by spectrophotometry 700 tissue samples from 495 patients in whom a mitochondrial disease was suspected. Isolated CoQ10-dependent activity deficiency led to identification of CoQ10 disease in eight cases. Eighteen patients presented CoQ10-dependent enzymatic deficiency associated with MRC defect by spectrophotometry in muscle or in fibroblasts. In order to validate our original observation and to establish if CoQ10 quantitative defect may be associated with multiple MRC enzymatic deficiency, we measured CoQ10 in this group of 18 patients. We found decreased CoQ10 levels by liquid chromatography coupled with tandem mass spectrometry detection (LC-MSMS) in eight patients out of 18 (45 %), thus confirming CoQ10 disease and its association with MRC enzymatic deficiency. Furthermore, CoQ10 disease cannot be ruled out in all other patients insofar as the quantitative assay could not always be performed in the affected tissue.

Results

Description of patients involved in the study

We studied 18 patients, including 10 males and eight females, ranging in age from day 1 to 76 years. Clinical presentations were very heterogeneous (Table 1). The age at onset of the disease was highly variable, ranging from (i) neonatal forms (seven cases with severe phenotypes), (ii) onset before 1 year of age (four cases with either Leigh syndrome or epileptic encephalopathy), (iii) childhood-onset (four cases including two myopathic forms and two complex phenotypes) to (iv) adult-onset (three cases with two myopathic presentations and one cerebellar ataxia). The 18 patients were divided into two different groups according to molecular results.
Table 1

Clinical phenotypes of patients presenting CoQ10-dependent enzymatic deficiency associated with MRC defect

Patient

Tissue

Sex

Age at biopsy

Age of onset

Heredity

Familial history

Neurological symptoms

Muscular symptoms

Other symptoms

Muscle histology

Enzymology

Diagnosis or molecular analyses

Patients with molecular diagnosis

P01a

Fibroblasts

M

D1

Neonatal

Recessive

Affected brother

  

Neonatal polyvisceral failure

Not done

Cx IV deficiency; segments II + III and G3P + III reduction

COQ2: homozygous mutation (c.437G > A; p.Ser146Asn)

P02

Muscle

M

54y

25y

Sporadic

No

Brain MRI: mild atrophy and lacunar strokes

CPEO

T2DM, hepatic steatosis, dyslipidemia

RRF (5–10 %) and Cox-fibers

Cxes I, II, IV and V deficiency; segments I + III and II + III reduction

Large-scale deletion of mtDNA

P03a

Fibroblasts

M

D1

Neonatal

de novo

No

Hypotonia, epilepsy and diffuse brain lesions

 

Neonatal polyvisceral failure: respiratory distress, hepatic failure, hypertrophic CMP, lactic acidosis ++

Not done

Cxes II and III deficiency; segments II + III and G3P + III reduction

MT-CYB: heteroplasmic mtDNA mutation (m.15635T > C; p.Ser297Pro)

P04a

Fibroblasts

M

15y

11y

Recessive

No

Ataxic sensory axonal neuropathy

CPEO

 

RRF and Cox-fibers (40 %)

Cxes I, II, III and IV deficiency; segments II + III and G3P + III reduction

SANDO with multiple mtDNA deletions and homozygous mutation in POLG: (c.911T > G; p.Leu304Arg)

P05

Muscle

F

54y

45y

Recessive

No

Ataxic sensory axonal neuropathy

CPEO

 

Lipid accumulation, RRF and Cox-fibers (20 %)

Cxes I, II, III, IV and V deficiency; segments I + III and II + III reduction

SANDO with multiple mtDNA deletions and compound heterozygous mutations in POLG: (c.752C > T/c.2452G > A; p.Thr251Ile/p.Gly848Ser)

P06a

Fibroblasts

M

D1

Neonatal

Recessive

No

Encephalopathy and hypotonia

 

Severe lactic acidosis, methylmalonic aciduria

Not done

Cxes II, III and IV deficiency; segments II + III and G3P + III reduction

SUCLG1: compound heterozygous mutations c.97 + 3G > C/c.509C > G (p.Pro170Arg)

P07

Muscle

F

18y

4y

Recessive

Blindness in paternal family

 

Bilateral ptosis, proximal myopathy, dysphonia, dysphagia, exercice intolerance

Retinitis pigmentosa, cyclic vomiting, hyperCPKemia

Lipid accumulation

Cxes I and III deficiency; segments I + III and II + III reduction

MADD with mutations in ETFDH

P08

Muscle

F

4 m

4 m

Recessive

Affected sister

Encephalopathy with refractory migrating partial seizures

  

Lipid accumulation

Cx I, II, III and IV deficiency; segments I + III and II + III reduction

Malignant migrating partial seizures with compound heterozygous mutations in TBC1D24: (c.468C > A/c.686C > T; p.Cys156X/p.Phe229Ser)

P09

Fibroblasts

M

D1

Neonatal

Recessive

No

Hypotonia

 

Hypertrophic CMP, dysmorphic, hepatic cytolysis, hypospadia

Glycogenic accumulation

Cxes II, III, IV and V deficiency; segments II + III and G3P + III reduction

CDG syndrome type Iq : homozygous mutation in SRD5A3 : (c.620T > G; p.Met207Arg)

P10a

Fibroblasts

M

3 m

Neonatal

de novo

No

Hypotonia, epilepsy, dysphagia

 

Dilated CMP, aortic dilatation

Glycogenic accumulation

Cxes III and IV deficiency; segments II + III and G3P + III reduction

1p36 deletion syndrome

Patients with no molecular diagnosis

P11

Muscle

M

76y

Adult

?

No

Cerebellar ataxia

  

2 RRF and Cox- fibers (20-30 %)

Cx IV deficiency; segments I + III and II + III reduction

Multiple mtDNA deletions

P12a

Fibroblasts

F

7 m

6 m

?

No

Leigh syndrome

  

Not done

Cx II deficiency; segments II + III and G3P + III reduction

mtDNA depletion, absence of mtDNA and POLG, SUCLA2, TK2 mutation

P13a

Muscle

F

41y

Childhood

Recessive

Consanguinity

Spastic tetraparesis, chorea, mental retardation

Myopathy

Glaucoma, cataract, lactic acidosis

RRF ++ 

Cx I deficiency; segments I + III and II + III reduction

Absence of mtDNA and POLG, OPA1, OPA3 mutation

P14

Muscle

F

33y

6 m

?

No

Epilepsy, spastic diplegia, dystonia, dyskinesia, tremor

  

1 Cox-fiber

Cxes III and V deficiency; segments I + III and II + III reduction

Absence of mtDNA and POLG, TTC19, DYT5 mutation

P15

Muscle

F

28 y

Childhood

Recessive

Affected siblings

Encephalopathy, mental retardation

  

Normal

Cxes II, III and V deficiency; segments I + III and II + III reduction

Absence of mtDNA mutation

P16

Fibroblasts

M

9y

Infancy

?

No

Psychomotor retardation, behavior disorders, dystonia, dyspraxia and basal ganglia involvement at brain MRI (Leigh)

  

Normal

Cxes II and III deficiency; segments II + III and G3P + III reduction

Absence of mtDNA mutation

P17

Fibroblasts

F

D3

D2

?

No

  

Unexplained severe respiratory failure

Normal

Cxes II, III deficiency; segments II + III and G3P + III reduction

Absence of mtDNA mutation

P18

Fibroblasts

M

2y

D18

?

No

Encephalopathy with refractory epilepsy

 

Microcephaly

Normal

Cxes III and IV deficiency; segments II + III and G3P + III reduction

Absence of mtDNA mutation

M male, F female, D day, m month, y year, CPK Creatine PhosphoKinase, CPEO Chronic Progressive External Ophthalmoplegia, T2DM Type 2 Diabetes Mellitus, CMP CardioMyoPathy, RRF Ragged Red Fibers, Cox cytochrome c oxydase, cx complex, mtDNA mitochondrial DNA, SANDO Sensory Ataxia Neuropathy Dysarthria and Ophthalmoplegia, MADD Multiple Acyl-CoA Dehydrogenation Deficiency, CDG Carbohydrate-Deficient Glycoprotein

aPatient deceased

The first group included 10 patients with identified mutations in responsible genes (Table 1). Patient P01 presented a severe neonatal multisystemic disease secondary to a homozygous missense mutation in the CoQ2 gene [18]. Spectrophotometric analysis in fibroblasts revealed a CoQ10-dependent activities defect (segments II + III and G3P + III reduction) associated with a complex IV deficiency (Table 2). Six patients (P02–P07) presented a mitochondrial disease or dysfunction secondary either to mtDNA abnormalities (P02 and P03) or to mutations in nuclear genes (P04–P07). Patient P02 had a large heteroplasmic mtDNA deletion responsible for Kearns–Sayre syndrome and patient P03 presented with a severe neonatal polyvisceral failure secondary to a heteroplasmic mtDNA mutation in the MT-CYB gene. Patients P04 and P05 presented with sensory ataxia neuropathy dysarthria and ophthalmoplegia (SANDO) phenotype associated with recessive mutations in POLG. Patient P06 had a neonatal encephalopathy with lactic acidosis and mild methylmalonic aciduria linked to mutations in the SUCLG1 gene. P07 had a diagnosis of multiple acyl-CoA dehydrogenation deficiency (MADD) with ETFDH mutation. The last three patients in the first group presented malignant migrating partial seizures with mutations in TBC1D24 (P08), CDG syndrome type Iq with SRD5A3-CDG mutations (P09) and 1p36 deletion syndrome (P10). Patients P02–P10 had a CoQ10-dependent activities deficiency (segments I + III or G3P + III and II + III reduction) associated with a multiple MRC defect in muscle or in fibroblasts (Table 2).
Table 2

Biochemical analysis of patient fibroblasts and muscle biopsies

OXPHOS activities (spectrophotometry)

I

II

III

IV

V

G3P + III

II + III

CS

CoQ10 quantity (LC-MSMS)

CoQ10

Fibroblast measurements

Control values (nmole/min/mg of proteins)

9.0–27.1

21.0–54.0

62.0–176.2

109.9–350.0

22.0–46.2

6.5–23.0

15.0–37.2

74.7–161.1

Control values (pmole/mg of proteins)

43.0–120.8

P01

11.2

27.7

89.7

29.2

33.5

2.3

7.5

156.2

P01

1.4

P03

11.5

18.5

21.3

177.7

34.1

4.1

12.5

106.7

P03

65.4

P04

7.5

18.6

40.2

108.2

30.5

4.7

8.6

95.0

P04

9.7

P06

11.6

20.6

47.9

78.1

37.6

5.5

10.8

116.6

P06

5.9

P09

12.0

13.4

53.4

57.0

15.8

4.1

8.9

80.9

P09

62.0

P10

13.5

22.9

54.4

65.0

28.3

5.4

12.0

148.2

P10

55.9

P12

10.9

17.6

76.6

173.3

25.0

4.4

10.1

102.5

P12

62.1

P16

11.2

20.7

57.4

134.9

38.3

6.1

14.5

124.0

P16

5.7

P17

12.9

20.0

61.5

181.7

29.3

5.6

14.7

130.3

P17

58.1

P18

14.4

22.5

39.4

78.9

39.3

5.5

13.2

147.0

P18

58.2

Muscle biopsy measurements

Control values (nmole/min/mg of proteins)

11.0–32.0

22.0–65.0

109.0–236.0

93.0-347.0

40.0–89.0

14.0–50.0

20.0–50.0

82.0–234.0

Control values (pmole/mg of proteins)

17.8 –22.2

P02

6.7

21.5

130.4

56.9

32.5

7.4

10.8

113.4

P02

16.0

P05

5.7

21.2

28.9

59.4

12.7

10.9

15.2

122.2

P05

35.5

P07

4.2

28.6

108.8

170.4

50.0

10.5

16.7

272.4

P07

25.9

P08

10.9

14.1

102.5

92.8

63.3

10.8

17.0

116.5

P08

5.7

P11

25.7

29.7

157.6

80.2

45.0

13.6

19.6

109.9

P11

6.2

P13

7.6

28.9

112.7

212.7

58.4

9.4

13.4

192.6

P13

22.4

P14

15.5

26.6

31.6

154.5

32.8

13.7

13.2

100.5

P14

22.2

P15

16.2

20.0

92.3

191.7

39.8

11.9

17.5

86.1

P15

7.1

Respiratory chain enzyme activities were measured spectrophotometrically. Results are expressed as absolute values for controls or patients (in nanomoles of substrate per minute per milligram of protein). CoQ10 quantity was measured by LC-MSMS. Results are expressed as absolute values for controls or patients (in picomoles per milligram of protein). Abnormal values are shown in italics

OXPHOS oxidative phosphorylation; LC-MSMS liquid chromatography coupled with tandem mass spectrometry detection

The second group included eight patients suspected of CoQ10 deficiency with an absence of molecular diagnosis. Except for individual P11, who developed cerebellar ataxia during adulthood, all patients had an early-onset disease ranging from neonatal period to childhood. They presented severe neurological symptoms including two Leigh syndromes (P12 and P16) and one child had an unexplained severe respiratory failure at birth (P17). In the second group, all patients presented a CoQ10-dependent enzymatic deficiency associated with MRC defect in muscle or in fibroblasts (Table 2).

Confirmation of CoQ10disease in eight patients by CoQ10 quantification

Quantitative analysis of CoQ10 in muscle or fibroblasts showed that eight patients presented CoQ10 content below normal values (Table 2). CoQ10 defect was found in five patients out of 10 in the first group and in three patients out of eight in the second group. CoQ10-deficient individuals were six males and two females, ranging in age from day 1 to 76 years. The age of onset was highly variable, ranging from neonatal forms to diseases appearing after 25 years of age, although six patients had childhood onset. One patient (P01) presented a polyvisceral failure at birth and all the others had neurological symptoms either isolated or combined with muscular and/or other signs. In the first group, the very low CoQ10 level observed in the fibroblasts of patient P01 confirmed the primary CoQ10 defect associated with the c.437G > A homozygous missense mutation (p.Ser146Asn) in the CoQ2 gene, involved in CoQ10 biosynthesis [18]. In the four other patients in the same group, CoQ10 defect was clearly secondary because the responsible genes were unrelated to CoQ10 biosynthesis. Three patients had a mitochondrial disease linked to a large mtDNA deletion (patient P02) or to mutations in POLG (patient P04) or SUCLG1 (patient P06). Patient P08 alone did not have a mitochondrial disease, her encephalopathy with refractory malignant migrating partial seizures being linked to mutations in the TBC1D24 gene. In the second group, low CoQ10 levels were found in three patients with no molecular diagnosis. Two patients were strongly suspected of having a mitochondrial disease: patient P11, who had a cerebellar ataxia with 20–30 % of COX-negative fibers and multiple mtDNA deletions in muscle, and patient P16 who presented with a Leigh syndrome. The last patient (P15) had an encephalopathy with intellectual disability but no histological sign of mitochondrial myopathy.

Discussion

While primary CoQ10 defects are rare, secondary defects have been observed in various pathologies. In a previous work, we suspected for the first time a secondary CoQ10 defect in a child with propionic acidemia, who succumbed to acute heart failure in the absence of decompensation of his metabolic condition [17]. CoQ10 deficiency was not evoked at the outset because CoQ10-dependent activities deficiency was associated with multiple MRC deficiency in the liver of the patient and it had been widely reported that enzymatic activities of MRC complexes are normal in CoQ10 disease [16]. However, it is likely that a secondary CoQ10 defect was involved in the development of heart complications leading to the child’s death and that oral CoQ10 supplementation would have been able to prevent cardiac failure if results had been obtained before acute clinical aggravation. This hypothesis is supported by a recent study, which describes a successful reversal of propionic acidemia-associated cardiomyopathy after treatment [19]. The child in this case presented with myocardial CoQ10 quantitative defect associated with signs of mitochondrial dysfunction such as enlarged mitochondria with atypical cristae and low MRC complex IV activity [19]. Several studies performed on cellular models of CoQ10 defect suggested a possible association with mitochondrial dysfunction: PDSS2 and COQ9 mutant fibroblasts presented a markedly reduced ATP synthesis and COQ2 mutant fibroblasts presented a partial defect in ATP synthesis, as well as significantly increased ROS production and oxidation of lipids and proteins [20, 21]. In 2013, Duberley and colleagues established the first pharmacologically-induced CoQ10 deficient cellular model in neuroblastoma-derived SH-SY5Y cells by using para-aminobenzoic acid (PABA). They showed that, after PABA treatment, SH-SY5Y cells presented a progressive decrease in the activities of CoQ10-dependent II + III segment but also a deficiency in MRC complexes I and IV. They also reported a concomitant decrease in the level of total cellular ATP with an increase of mitochondrial oxidative stress [22]. Lastly, deficiency of complexes I, II, III and/or IV has also been previously reported in association with CoQ10 defect in the patient’s fibroblasts, muscle or kidney [8, 11, 18, 23].

Today, in most diagnostic laboratories, a spectrophotometric deficiency in one or several MRC enzymes associated with a decrease in CoQ10-dependent activities is not considered to be a sign of a CoQ10 disease, leading to a possible under-estimation of the frequency of this disorder. With the aim of achieving a better diagnostic approach, we quantified CoQ10 by LC-MSMS in 18 patients presenting a CoQ10-dependent enzymatic deficiency associated with a MRC defect by spectrophotometry. CoQ10 quantitative analysis in muscle or in fibroblast cells confirmed CoQ10 disease in eight patients (45 %). These data show that a primary CoQ10 defect can be associated with MRC enzymatic deficiency because patient P01, who carried a deleterious homozygous mutation (c.437G > A; p.Ser146Asn) in the CoQ2 gene, also presented a complex IV deficiency in muscle. Our data also confirm that a secondary CoQ10 defect can be associated with mitochondrial disease. Indeed, three other patients with a low CoQ10 level presented a respiratory chain deficiency linked to mtDNA deletion (patient P02) or to mutations in POLG and SUCLG1 genes (patients P04 and P06). Secondary CoQ10 defect has already been reported in patients with mitochondrial diseases or dysfunctions including Kearns–Sayre syndrome [24], mtDNA depletion and PEO [5] or mutations in ETFDH coding for electrontransferring-flavoprotein dehydrogenase and causing MADD [8, 9]. Secondary CoQ10 defect has also been described in non-mitochondrial disorders linked to genes such as APTX coding for aprataxin and causing ataxia occulomotor-apraxia [7], BRAF coding for serine/threonine-protein kinase B-Raf and causing cardiofaciocutaneous syndrome [10], ACADVL causing very long-chain Acyl-CoA dehydrogenase deficiency or NPC causing Niemann-Pick-type C disease [11]. Here, we report for the first time a secondary CoQ10 defect associated with mutations in the TBC1D24 gene, leading to malignant migrating partial seizures (Patient P08). The mechanisms linking CoQ10 defect and decreased activity of MRC complexes are unknown. Studies in patients with metabolic diseases showed an increase in oxidative stress-markers and a decrease in antioxidant defences [25]. More specifically, ubiquinol depletion in patient tissues may lead to increased reactive oxygen species activity [26] and, since all enzymes of the MRC are susceptible to free radical induced oxidative damage [27], we can hypothesize that CoQ10-independent MRC dysfunction may result from a high level of mitochondrial oxidative stress creating an imbalance with the CoQ10 antioxidant capacity, as previously evoked [25]. In parallel, a possible reason for a secondary CoQ10 defect resulting from a primary MRC deficiency is that the enzymes involved in CoQ10 biosynthesis are found in a supercomplex in the inner mitochondrial membrane [28]. We hypothesize that the increased oxidative stress resulting from a primary MRC deficiency may inhibit these enzymes resulting in a secondary CoQ10 defect.

Conclusions

In conclusion, our work highlights the probability that, based on spectrophotometric analysis, the frequency of CoQ10 disease is underestimated in routine clinical practice. Several studies, which performed a systematic CoQ10 quantification on muscle biopsies from pediatric and adult populations presenting a wide range of clinical phenotypes, also reported an underestimation of CoQ10 defects and proposed a systematic evaluation of CoQ10 content in all muscle biopsies [5, 29, 30]. However, first-line CoQ10 quantification seems difficult to set up as a routine analysis in all diagnosis laboratories. Based on our observations, we suggest that CoQ10 quantification be performed in all tissues presenting a spectrophotometric deficiency of CoQ10-dependent enzymes, associated or not with MRC defect, regardless of the patient’s age, clinical presentation or molecular diagnosis. This could prove of great value in clinical practice for the diagnosis of a disease that can be improved by CoQ10 supplementation.

Methods

Patients

All patients were explored in the Reference Centre for Mitochondrial Disease (CHU of Nice, France). Selection of the 18 patients was based on the following inclusion criteria: (1) availability of a muscle sample or fibroblast culture and (2) spectrophotometric deficiency of CoQ10-dependent activities (reduction of segments I + III or G3P + III and II + III) associated with MRC defect in muscle or in fibroblasts. The following data were systematically collected: sex, age at biopsy, age of onset, heredity, familial history, clinical presentation, brain MRI, metabolic screening, mitochondrial enzymatic studies, histological and molecular analyses. The age of onset of clinical symptoms ranged from neonatal period to 45 years of age. Blood and tissue samples were obtained after adult patients and parents of affected children had given informed consent.

Patients were divided into two groups (Table 1), according to the results of molecular analysis: (1) individuals with a molecular diagnosis, carrying mutations in mtDNA or in nuclear genes and, (2) individuals with no molecular diagnosis.

Cell culture

Primary fibroblast cultures were obtained from patient skin punches, using standard procedures, in RPMI medium supplemented with 10 % Fetal Bovine Serum, 45 μg/ml uridine and 275 μg/ml sodium pyruvate. Cultures were incubated at 37 ℃ with 5 % CO2.

OXPHOS spectrophotometric measurements

Enzymatic spectrophotometric measurements of the OXPHOS respiratory chain complexes and citrate synthase were performed at 37 ℃ on muscle crude homogenates or fibroblasts according to standard procedures [31]. Proteins were measured according to Bradford microassay [32] and results were expressed as nmole/min/mg of proteins.

Coenzyme Q10 quantification

Total coenzyme Q10 was extracted from tissues and analyzed by reverse phase liquid chromatography separation (column C18 symmetry 150 × 2.1 mm, 3.5 µm, Waters, France) as previously described [33]. Detection and quantification were done by mass spectrometry using an API 3000 tandem mass spectrometer (ABSciex, France) equipped with an APCI source. CoQ10 and CoQ9 were analyzed in the positive mode using the following m/z 864 → 197 and 796 → 197 transitions. CoQ9 was used as internal standard for quantification. External calibration was performed using CoQ10 solutions. A stock solution was prepared by dissolving 10 mg of CoQ10 in 4 ml of methanol/chloroform (98:2 v/v). This solution was stable for 3 months at −80 °C. The working solutions were prepared daily by diluting the stock solution into methanol to provide a range of 0.05–1 µmol/L. The intra-assay and inter-assay CV’s were, respectively, 5.7 and 6.3 % for a CoQ10 concentration of 0.25 µmol/L.

Declarations

Author’s contributions

Study conception and design: KF, AC, VP-F. LC-MSMS experiments: JFB. Molecular analysis: SA, SB, CR. Biochemical explorations: KF, CC. Data collection and analysis: KF, AC, JFB, SA, SB, CR, VP-F. Manuscript drafting: KF, AC, VP-F. Study supervision: VP-F. All authors read and approved the final manuscript.

Acknowledgements

Véronique Paquis-Flucklinger received support from the CHU of Nice. We thank George Morgan for careful reading of the manuscript.

Competing interests

The authors declare that they have no competing interests.

Open AccessThis article is distributed under the terms of the Creative Commons Attribution 4.0 International License (http://creativecommons.org/licenses/by/4.0/), which permits unrestricted use, distribution, and reproduction in any medium, provided you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made. The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated.

Authors’ Affiliations

(1)
School of Medicine, IRCAN, UMR CNRS 7284/INSERM U1081/UNS, Nice Sophia-Antipolis University
(2)
Department of Medical Genetics, Nice Teaching Hospital, National Centre for Mitochondrial Diseases
(3)
Department of Biochemistry, Robert Debre Hospital

References

  1. Turunen M, Olsson J, Dallner G. Metabolism and function of coenzyme Q. Biochim Biophys Acta. 2004;1660:171–99.PubMedView ArticleGoogle Scholar
  2. Quinzii CM, Hirano M. Coenzyme Q and mitochondrial disease. Dev Disabil Res Rev. 2010;16:183–8.PubMedPubMed CentralView ArticleGoogle Scholar
  3. Desbats MA, Lunardi G, Doimo M, Trevisson E, Salviati L. Genetic bases and clinical manifestations of coenzyme Q10 (CoQ 10) deficiency. J Inherit Metab Dis. 2015;38:145–56.PubMedView ArticleGoogle Scholar
  4. Matsuoka T, Maeda H, Goto Y, Nonaka I. Muscle coenzyme Q10 in mitochondrial encephalomyopathies. Neuromuscul Disord. 1991;1:443–7.PubMedView ArticleGoogle Scholar
  5. Sacconi S, Trevisson E, Salviati L, Aymé S, Rigal O, Redondo AG, et al. Coenzyme Q10 is frequently reduced in muscle of patients with mitochondrial myopathy. Neuromuscul Disord. 2010;20:44–8.PubMedView ArticleGoogle Scholar
  6. Montero R, Grazina M, López-Gallardo E, Montoya J, Briones P, Navarro-Sastre A, et al. Coenzyme Q10 deficiency in mitochondrial DNA depletion syndromes. Mitochondrion. 2013;13:337–41.PubMedView ArticleGoogle Scholar
  7. Quinzii CM, Kattah AG, Naini A, Akman HO, Mootha VK, DiMauro S, et al. Coenzyme Q deficiency and cerebellar ataxia associated with an aprataxin mutation. Neurology. 2005;64:539–41.PubMedView ArticleGoogle Scholar
  8. Gempel K, Topaloglu H, Talim B, Schneiderat P, Schoser BG, Hans VH, et al. The myopathic form of coenzyme Q10 deficiency is caused by mutations in the electron-transferring-flavoprotein dehydrogenase (ETFDH) gene. Brain. 2007;130:2037–44.PubMedPubMed CentralView ArticleGoogle Scholar
  9. Liang WC, Ohkuma A, Hayashi YK, López LC, Hirano M, Nonaka I, et al. ETFDH mutations, CoQ10 levels, and respiratory chain activities in patients with riboflavin-responsive multiple acyl-CoA dehydrogenase deficiency. Neuromuscul Disord. 2009;19:212–6.PubMedView ArticleGoogle Scholar
  10. Aeby A, Sznajer Y, Cavé H, Rebuffat E, Van Coster R, Rigal O, et al. Cardiofaciocutaneous (CFC) syndrome associated with muscular coenzyme Q10 deficiency. J Inherit Metab Dis. 2007;30:827.PubMedView ArticleGoogle Scholar
  11. Buján N, Arias A, Montero R, García-Villoria J, Lissens W, Seneca S, et al. Characterization of CoQ10 biosynthesis in fibroblasts of patients with primary and secondary CoQ10 deficiency. J Inherit Metab Dis. 2014;37:53–62.PubMedView ArticleGoogle Scholar
  12. Geromel V, Darin N, Chrétien D, Bénit P, DeLonlay P, Rötig A, et al. Coenzyme Q(10) and idebenone in the therapy of respiratory chain diseases: rationale and comparative benefits. Mol Genet Metab. 2002;77:21–30.PubMedView ArticleGoogle Scholar
  13. Trevisson E, DiMauro S, Navas P, Salviati L. Coenzyme Q deficiency in muscle. Curr Opin Neurol. 2011;24:449–56.PubMedView ArticleGoogle Scholar
  14. García-Corzo L, Luna-Sánchez M, Doerrier C, Ortiz F, Escames G, Acuña-Castroviejo D, et al. Ubiquinol-10 ameliorates mitochondrial encephalopathy associated with CoQ deficiency. Biochim Biophys Acta. 2014;1842:893–901.PubMedView ArticleGoogle Scholar
  15. Rustin P, Munnich A, Rötig A. Mitochondrial respiratory chain dysfunction caused by coenzyme Q deficiency. Methods Enzymol. 2004;382:81–8.PubMedView ArticleGoogle Scholar
  16. Rötig A, Mollet J, Rio M, Munnich A. Infantile and pediatric quinone deficiency diseases. Mitochondrion. 2007;7(Suppl):S112–21.PubMedView ArticleGoogle Scholar
  17. Fragaki K, Cano A, Benoist JF, Rigal O, Chaussenot A, Rouzier C, et al. Fatal heart failure associated with CoQ10 and multiple OXPHOS deficiency in a child with propionic acidemia. Mitochondrion. 2011;11:533–6.PubMedView ArticleGoogle Scholar
  18. Diomedi-Camassei F, Di Giandomenico S, Santorelli FM, Caridi G, Piemonte F, Montini G, et al. COQ2 nephropathy: a newly described inherited mitochondriopathy with primary renal involvement. J Am Soc Nephrol. 2007;18:2773–80.PubMedView ArticleGoogle Scholar
  19. Baruteau J, Hargreaves I, Krywawych S, Chalasani A, Land JM, Davison JE, et al. Successful reversal of propionic acidaemia associated cardiomyopathy: evidence for low myocardial coenzyme Q10 status and secondary mitochondrial dysfunction as an underlying pathophysiological mechanism. Mitochondrion. 2014;17:150–6.PubMedView ArticleGoogle Scholar
  20. Quinzii CM, López LC, Von-Moltke J, Naini A, Krishna S, Schuelke M, et al. Respiratory chain dysfunction and oxidative stress correlate with severity of primary CoQ10 deficiency. FASEB J. 2008;22:1874–85.PubMedPubMed CentralView ArticleGoogle Scholar
  21. Quinzii CM, López LC, Gilkerson RW, Dorado B, Coku J, Naini AB, et al. Reactive oxygen species, oxidative stress, and cell death correlate with level of CoQ10 deficiency. FASEB J. 2010;24:3733–43.PubMedPubMed CentralView ArticleGoogle Scholar
  22. Duberley KE, Abramov AY, Chalasani A, Heales SJ, Rahman S, Hargreaves IP. Human neuronal coenzyme Q10 deficiency results in global loss of mitochondrial respiratory chain activity, increased mitochondrial oxidative stress and reversal of ATP synthase activity: implications for pathogenesis and treatment. J Inherit Metab Dis. 2013;36:63–73.PubMedView ArticleGoogle Scholar
  23. Lalani SR, Vladutiu GD, Plunkett K, Lotze TE, Adesina AM, Scaglia F. Isolated mitochondrial myopathy associated with muscle coenzyme Q10 deficiency. Arch Neurol. 2005;62:317–20.PubMedView ArticleGoogle Scholar
  24. Zierz S, Jahns G, Jerusalem F. Coenzyme Q in serum and muscle of 5 patients with Kearns-Sayre syndrome and 12 patients with ophthalmoplegia plus. J Neurol. 1989;236:97–101.PubMedView ArticleGoogle Scholar
  25. Mc Guire PJ. Parikh A, Diaz GA. Profiling of oxidative stress in patients with inborn errors of metabolism. Mol Genet Metab. 2009;98:173–80.PubMedPubMed CentralView ArticleGoogle Scholar
  26. Genova ML, Pich MM, Biondi A, Bernacchia A, Falasca A, Bovina C, et al. Mitochondrial production of oxygen radical species and the role of Coenzyme Q as an antioxidant. Exp Biol Med (Maywood). 2003;228:506–13.PubMedGoogle Scholar
  27. Zhang Y, Marcillat O, Giulivi C, Ernster L, Davies KJ. The oxidative inactivation of mitochondrial electron transport chain components and ATPase. J Biol Chem. 1990;265:16330–6.PubMedGoogle Scholar
  28. Hsieh EJ, Gin P, Gulmezian M, Tran UC, Saiki R, Marbois BN, et al. Saccharomyces cerevisiae Coq9 polypeptide is a subunit of the mitochondrial coenzyme Q biosynthetic complex. Arch Biochem Biophys. 2007;463:19–26.PubMedPubMed CentralView ArticleGoogle Scholar
  29. Montero R, Artuch R, Briones P, Nascimento A, García-Cazorla A, Vilaseca MA, et al. Muscle coenzyme Q10 concentrations in patients with probable and definite diagnosis of respiratory chain disorders. BioFactors. 2005;25:109–15.PubMedView ArticleGoogle Scholar
  30. Miles MV, Miles L, Tang PH, Horn PS, Steele PE, DeGrauw AJ, et al. Systematic evaluation of muscle coenzyme Q10 content in children with mitochondrial respiratory chain enzyme deficiencies. Mitochondrion. 2008;8:170–80.PubMedView ArticleGoogle Scholar
  31. Rustin P, Chretien D, Bourgeron T, Gérard B, Rötig A, Saudubray JM, et al. Biochemical and molecular investigations in respiratory chain deficiencies. Clin Chim Acta. 1994;228:35–51.PubMedView ArticleGoogle Scholar
  32. Bradford MM. A rapid and sensitive method for the quantitation of microgram quantities of protein utilizing the principle of protein-dye binding. Anal Biochem. 1976;72:248–54.PubMedView ArticleGoogle Scholar
  33. Benoist JF, Rigal O, Nivoche Y, Martin C, Biou D, Lombès A. Differences in coenzyme Q10 content in deltoid and quadriceps muscles. Clin Chim Acta. 2003;329:147–8.PubMedView ArticleGoogle Scholar

Copyright

© Fragaki et al. 2016